Mobilan - Panacela Labs

Drug Profile

Mobilan - Panacela Labs

Alternative Names: M-VM3; MVAME03; Prostate cancer vaccine - Pancela/Cleveland BioLabs

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Childrens Cancer Institute Australia for Medical Research; Cleveland BioLabs; Cleveland Clinic; Roswell Park Cancer Institute
  • Developer Panacela Labs
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Toll-like receptor 5 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 01 Sep 2017 Panacela completes a phase I trial in Prostate cancer in Russia (Intratumoural) (NCT02654938)
  • 01 Jul 2016 Phase-I/II clinical trials in Prostate cancer (Neoadjuvant therapy, Newly diagnosed) in Russia (Intratumoural) (NCT02844699)
  • 01 Jan 2015 The US FDA approves IND application for mobilan in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top